owering of very long chain fatty acids in patients with X-linked adrenoleukodystrophy (X-ALD): A biochemical study.
Recruiting
- Registration Number
- NL-OMON22008
- Lead Sponsor
- Trial medication was provided by Merck, Sharp and Dome (MSD)
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 20
Inclusion Criteria
1. Male patients with X-ALD (confirmed by biochemical analysis or mutation analysis of the ABCD1 gene);
2. 18 years or older;
3. Able to give informed consent and visit the hospital;
4. No contraindications for use of trial medication.
Exclusion Criteria
1. Use of another cholesterol lowering drug;
2. Liver disease or CK more than 3 times baseline level;
3. Use of very long chain fatty acid lowering therapy (e.g. Lorenzo's oil) in the 8 weeks preceding the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Very long chain fatty acid levels (in plasma and erythrocytes).
- Secondary Outcome Measures
Name Time Method